Enzastaurin (LY317615) 化学構造
分子量: 515.61

高品質保証

カスタマーフィードバック(3)

MSDS

製品説明

  • Compare PKC Inhibitors
    PKC製品生物活性の比較
  • 研究分野

製品の説明

生物活性

製品説明 Enzastaurin (LY317615) はプロテインキナーゼCβ選択阻害剤、 PKCβ, PKCα, PKCγ と PKCε を作用すると、 IC50 がそれぞれ6 nM, 39 nM, 83 nM 、 110 nMとなる.
ターゲット

PKCβ

PKCα

PKCγ

PKCε

IC50

6 nM

39 nM

83 nM

110 nM [1]

In vitro試験 Enzastaurin application results in a marked dose-dependent inhibition of growth in all MM cell lines investigated, including MM.1S, MM.1R, RPMI 8226 (RPMI), RPMI-Dox40 (Dox40), NCI-H929, KMS-11, OPM-2, and U266, with IC50 from 0.6-1.6 μM. Enzastaurin direct impacts human tumor cells, inducing apoptosis and suppressing proliferation in cultured tumor cells. Enzastaurin also suppresses the phosphorylation of GSK3βser9, ribosomal protein S6S240/244, and AKTThr308 while having no direct effect on VEGFR phosphorylation. [1] Enzastaurin increases apoptosis in malignant lymphocytes of CTCL. When combined with GSK3 inhibitors, enzastaurin demonstrated an enhancement of cytotoxicity levels. Treatment with a combination of enzastaurin and the GSK3 inhibitor AR-A014418 led to increased levels of β-catenin total protein and β-catenin-mediated transcription. Blocking of β-catenin-mediated transcription or small hairpin RNA (shRNA) knockdown of β-catenin induced the same cytotoxic effects as that of enzastaurin plus AR-A014418. Additionally, treatment with enzastaurin and AR-A014418 decreased the mRNA levels and surface expression of CD44. [2]
In vivo試験 Treatment of xenografts with Enzastaurin and radiation produced greater reductions in density of microvessels than either treatment alone. The decrease in microvessel density corresponded to delayed tumor growth. [3]
臨床試験 Phase II clinical trials of enzastaurin for the treatment of neoplasms have been completed.
特集

プロトコル (参考用のみ)

キナーゼアッセイ:

[1]

Kinase inhibition assays The inhibition of PKCβII, PKCα, PKCε, or PKCγ activity by enzastaurin is determined using a filter plate assay format measuring 33P incorporation into myelin basic protein substrate. Reactions are done in 100 μL reaction volumes in 96-well polystyrene plates with final conditions as follows: 90 mM HEPES (pH 7.5), 0.001% Triton X-100, 4% DMSO, 5 mM MgCl2, 100 μM CaCl2, 0.1 mg/mL phosphatidylserine, 5 μg/mL diacetyl glyerol, 30 μM ATP, 0.005 μCi/μL 33ATP, 0.25 mg/mL myelin basic protein, serial dilutions of enzastaurin (1-2,000 nM), and recombinant human PKCβII, PKCα, PKCε, or PKCγ enzymes (390, 169, 719, or 128 pM, respectively). Reactions are started by addition of the enzyme and incubated at room temperature for 60 minutes. They are then quenched with 10% H3PO4, transferred to multiscreen anionic phosphocellulose 96-well filter plates, incubated for 30 to 90 minutes, filtered and washed with 4 volumes of 0.5% H3PO4 on a vacuum manifold. Scintillation cocktail is added and plates are read on a Microbeta scintillation counter. IC50 values are determined by fitting a three-variable logistic equation to the 10-point dose-response data using ActivityBase 4.0.

細胞アッセイ:

[1]

細胞株 HCT116 and U87MG cells
濃度 0.3-4 μM
反応時間 72 hours
実験の流れ

Induction of apoptosis by enzastaurin is measured by nucleosomal fragmentation and terminal deoxynucleotidyl transferase-mediated nick-end labeling (TUNEL) and staining in HCT116 and U87MG cell lines. Briefly, 5 × 103 cells are plated per well in 96-well plates (1% FBS-supplemented media conditions), incubated with or without Enzastaurin for 48 to 72 hours. The absorbance values are normalized to those from control-treated cells to derive a nucleosomal enrichment factor at all concentrations as per the manufacturer's protocol. The concentrations studied ranges from 0.1 to 10 μM. In situ TUNEL staining is assayed with the In situ Cell Death Detection, Fluorescein kit. Cells (7.5 ?104) are plated per well in 6-well plates and incubated 72 hours in 1% FBS-supplemented media ?Enzastaurin. Fluorescein-labeled DNA strand breaks are detected with the BD epics flow cytometer. Ten thousand, single-cell, FITC-staining events are collected for each test.

動物実験: [1] [3]

動物モデル Athymic nude mice; Mouse besring human MM tumors
製剤 10% acacia in water; dissolved in 100% ethanol and diluted 1:10 in D5W
投薬量 75 mg/kg twice daily; 30 mg/kg twice daily
投与方法 By gavage

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDogMonkeyBaboon
Weight (kg)0.020.151.80.40.0810312
Body Surface Area (m2)0.0070.0250.150.050.020.50.240.6
Km factor361285201220
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

参考

化学情報

Download Enzastaurin (LY317615) SDF
分子量 515.61
化学式

C32H29N5O2

CAS No. 170364-57-5
保管 3年-20℃
2年-80℃in solvent
別名 N/A
溶解度 (25°C) * In vitro DMSO 30 mg/mL (58.18 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 15% Captisol 30 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
化学名 3-(1-methyl-1H-indol-3-yl)-4-(1-(1-(pyridin-2-ylmethyl)piperidin-4-yl)-1H-indol-3-yl)-1H-pyrrole-2,5-dione

文献中の引用 (13)

技術サポート&よくある質問(FAQ)

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)

他の質問がある場合は、お気軽くお問合せください。

* 必須

Related PKC 阻害剤

  • SD-208

    SD-208は1種のセレクティブTGF-βRI (ALK5)阻害剤です。このIC50値は48 nMです。選択性について、TGF-βRI (ALK5)はTGF-βRIIより100倍以上が高くなります。

  • LDN-214117

    LDN-214117は1種の有効的でセレクティブBMP I型受容体キナーゼALK2阻害剤です。このIC50値は24 nMです。

  • Staurosporine

    Staurosporineは1種の有効なPKC阻害剤で、無細胞試験でPKCα、PKCγ とPKCηに作用します。そして、これらのIC50値は2 nM、5 nM と 4 nMそれぞれに分かれます。StaurosporineはPKCδ(20 nM)とPKCε(73 nM)に作用することが弱くて、PKCζ (1086 nM)に対する活性も低いですが、他のキナーゼ(例えば、PKA、PKG、S6K、CaMKII等)に抑制活性を現れます。臨床3期。

  • Sotrastaurin

    Sotrastaurinは、強力な選択的な汎PKC阻害剤で、0.22nMのKiで、高くPKCθを妨げます。

    Features:Unlike former PKC inhibitors, Sotrastaurin does not enhance apoptosis of murine T-cell blasts in a model of activation-induced cell death.

  • Go 6983

    Go 6983 はパン阻害剤、PKCα、PKCβ、PKCγ、 PKCδ、 PKCζを妨げて、IC50 がそれぞれ 7 nM、 7 nM、 6 nM、 10 nM と 60 nMです。

  • GF109203X

    GF109203X is a potent PKC inhibitor with IC50 of 20 nM, 17 nM, 16nM, and 20 nM for PKCα, PKCβI, PKCβII, and PKCγ, respectively, showing more than 3000-fold selectivity for PKC as compared to EGFR, PDGFR and insulin receptor.

    Features:Greater selectivity than PKC inhibitor staurosporine. GF109203X is a chemical probe for studying PKC signal transduction pathways. Potential for use in a variety of cancers.

  • Go6976

    Go6976は1種の有効なPKC 阻害剤で、PKC (ネズミ脳)、PKCαと PKCβ1に対するIC50値は7.9nM、2.3 nMと6.2 nMそれぞれに分かれます。尚、Go6976もJAK2 と Flt3の有効な阻害剤です。

  • Ro 31-8220 Mesylate

    Ro 31-8220 is a pan-PKC inhibitor with IC50 of 5 nM, 24 nM, 14 nM, 27 nM, and 24 nM for PKC-α, PKC-βI, PKC-βII, PKC-γ, and PKC-ε, respectively, and also shows potent inhibition against MAPKAP-K1b, MSK1, GSK3β and S6K1.

  • Dequalinium Chloride

    Dequalinium Chlorideは PKC 阻害剤、 IC50 が7-18 μMで、そのうえ、アパミンに敏感な選択的なブロッカーK+ channelsIC50 が1.1 μMです。

最近チェックしたアイテム

Tags: Enzastaurin (LY317615)を買う | Enzastaurin (LY317615)供給者 | Enzastaurin (LY317615)を購入する | Enzastaurin (LY317615)費用 | Enzastaurin (LY317615)生産者 | オーダーEnzastaurin (LY317615) | Enzastaurin (LY317615)代理店
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
お問い合わせ